pretty far otm there , but thats ok . i got 40s and 35s , at least the spread is always fairly reasonable , i been trading calls since $9 in this.
Celldex Therapeutics, Inc.’s (CLDX) innovative brain cancer, breast cancer and ultraorphan drugs have substantial commercial opportunities and are targeting highly unmet medical needs while reporting very strong data, says Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.
“Celldex has several innovative drugs; all of them have a very clear commercial opportunity, where they are not directly competing with any existing drugs, but their leading drugs are in breast cancer and in brain cancer. In breast cancer, they’ve reported very strong Phase II data; they’re starting a Phase III on that drug, and so it doesn’t have a lot of catalysts coming up, but the Phase II data in my view was spectacular,” Peaker said. Additionally, Celldex has a very innovative drug in the brain cancer space, and a clear biological test to identify patients that are likely to be responders, Peaker says. The company also has an orphan drug in development that adds to its collection of differentiated drugs that are targeting unmet medical needs.
“There are a lot of exciting developments there. They also have an orphan, an ultraorphan drug in development that’s in early stages, which is — we’re going to get some preliminary efficacy, the first efficacy around year end. So they have a number of drugs out there that are targeting really highly unmet medical need with very differentiated profiles and with catalysts on the near-term horizon,” Peaker said.
was over on vicl pumping like mad before it tanked , im long here with some calls mostly a little $ i already made on this and a little cldx snithzel ...just saying , whats your obsession here dude , do you not have a life...job
Celldex Therapeutics was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. A critical component of this strategy includes combining therapeutic approaches to leverage the power of the immune system’s response. We accomplish this by not only fully maximizing our own pipeline but also by identifying promising external technologies that will complement it. Likewise, when appropriate, we consider entering into partnerships for Celldex-owned programs that will enhance our mutual ability to advance novel science and accelerate the development of truly life-changing therapies for patients. For more information on partnering opportunities, please email cldx
squeeze starts now , they dont wanna hold after today
FRANK...take your politicol shiz to the dang hal board already. i mean cmon man
why wil they need it m hedge ? they have 180 mill in cash..the street is talking out there #$%$ because its getting away from them here.